SCH-50971

SCH-50971
Clinical data
Other namesSch-50971
Routes of
administration
Oral
Drug classHistamine H3 receptor agonist
ATC code
  • None
Identifiers
  • 5-[(3R,4R)-4-methylpyrrolidin-3-yl]-1H-imidazole
PubChem CID
ChemSpider
ChEMBL
Chemical and physical data
FormulaC8H13N3
Molar mass151.213 g·mol−1
3D model (JSmol)
  • C[C@H]1CNC[C@@H]1C2=CN=CN2
  • InChI=1S/C8H13N3/c1-6-2-9-3-7(6)8-4-10-5-11-8/h4-7,9H,2-3H2,1H3,(H,10,11)/t6-,7-/m0/s1
  • Key:KTEPQLOOQDLKHF-BQBZGAKWSA-N

SCH-50971 is a histamine H3 receptor agonist which was under development for the treatment of anxiety disorders, gastrointestinal disorders, and migraine but was never marketed.

Pharmacology

The drug acts as a potent, selective, and high-affinity agonist of the histamine H3 receptor. It has negligible affinity for the histamine H1 receptor and other assessed receptors. The drug is also not a histamine H2 receptor antagonist. It has greatly improved selectivity compared to the earlier selective histamine H3 receptor agonist (R)-α-methylhistamine. The drug is orally active and shows anti-allergy effects, antimigraine effects, sedative and hypnotic effects, and hypolocomotion in animals. In terms of chemical structure, it is a cyclized pyrrolidine derivative of histamine.

Development

SCH-50971 was under development by Schering-Plough. It reached the discovery or preclinical research stage of development. The development of the drug was discontinued by 2001. SCH-50971 was first described in the scientific literature by 1994.

See also